Avecho Biotechnology Share Price and Company Fundamentals
Last traded: Yesterday at 1:11 AM
Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 is based in Clayton, Australia.
|Primary activities||Avecho is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system, TPM.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||2A Westall Road Unit A8 Clayton VIC 3168 Australia|
|Phone / Fax||61 3 9002 5000 / 61 3 9002 5000|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Avecho Biotechnology does not pay dividends.
As of Jul 2021, following are the company executives and directors listed on Avecho Biotechnology.
|Dr. Roksan Libinaki||COO & GM of Animal Health & Nutrition||239.12k|
|Dr. Paul Gavin||CEO & Chief Scientific Officer||266.1k|
|Ms. Melanie Jaye Leydin B.Bus, C.A., CA||Company Sec. & CFO||47|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Avecho Biotechnology is 34.89M and its enterprise value is 33.04M. The enterprise value to revenue ratio of AVE is 85.91.
The AVE's stocks Beta value is 2.07 making it 107% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Avecho Biotechnology (AVE)
Avecho Biotechnology (ASX:AVE) Frequently Asked Questions
1. What is Avecho Biotechnology's Stock Symbol?
Avecho Biotechnology trades on ASX under the ticker symbol "AVE".
2. What is Avecho Biotechnology's stock price today?
One share of AVE stock can currently be purchased for approximately $0.019.
3. How can I contact Avecho Biotechnology?
Avecho Biotechnology's mailing address is 2A Westall Road Unit A8 Clayton VIC 3168 Australia. The company can be reached via phone at 61 3 9002 5000.
4. What is Avecho Biotechnology's official website?
The official website of Avecho Biotechnology is http://avecho.com.au.
5. Which share registry manages Avecho Biotechnology's stock?
Avecho Biotechnology's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.